[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555002":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":42,"responsibleParty":60,"collaborators":31,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":31,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":31,"overallStatus":45,"whyStopped":31,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of Missouri-Columbia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Empagliflozin","EXPERIMENTAL","10mg Empagliflozin daily for 12 weeks",[13],"Drug: Empagliflozin 10 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","10mg Placebo daily for 12 weeks",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Empagliflozin 10 MG",[9],[26],"Active",{"type":22,"name":15,"description":17,"armGroupLabels":28,"otherNames":29},[15],[30],"Inactive",null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Camila Manrique, MD","CONTACT","(573) 882-2554","manriquec@health.missouri.edu",{"name":39,"role":35,"phone":40,"phoneExt":31,"email":41},"Andrea Atkins, BSN","(573) 884-1222","wiesa@health.missouri.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University of Missouri","RECRUITING","Columbia","Missouri","65211","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-92.33407,38.95171,{"lat":55,"lon":54},[58],{"name":39,"role":35,"phone":59,"phoneExt":31,"email":41},"573-884-1222",{"type":61,"investigatorFullName":34,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Professor of Medicine","100555002","phase-2-empagliflozin-reversal-of-arterial-stiffness-in-aging-100555002",false,"NCT06506422","Empagliflozin Reversal of Arterial StiffnEss in Aging","SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging","ERASE-Aging","Inclusion Criteria:\n\n* Able to provide consent\n* 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)\n* Stable anti-hypertensive medication regimen (if in use) for at least 90 days\n* Evidence of arterial stiffening (defined as carotid-femoral PWV \\>\u002F= 8 m\u002Fs) at the time of screening visit.\n\nExclusion Criteria:\n\n* Diabetes\n* BMI\\>\u002F= 45kg\u002Fm2\n* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke\n* Estimated glomerular filtration rate GFR \\\u003C 29 mL\u002Fmin\n* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)\n* Excessive alcohol consumption (\\>14 drinks\u002Fweek for men, \\>7 drinks\u002Fweek for women)\n* Use of hormone replacement therapy\n* Body weight change ≥10% within the last 6 months\n* Uncontrolled hypertension during screening visit (\\>180\u002F110 mmHg)\n* Symptomatic hypotension and\u002For a SBP \\\u003C100 mmHg\n* History of ketoacidosis\n* High fall risk per assessment of study physician and\u002For safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements)\n* Anticipated need of prolonged fasting\n* History of recurrent UTIs or mycotic genital infections\n* Following a low-carbohydrate diet (\\\u003C20 grams\u002Fday)\n* Participation in regular exercise \\> 3 days\u002Fweek per week at a moderate or vigorous intensity\n* Known sensitivity to nitrate medications",true,"ALL","60 Years","80 Years",{"count":76,"type":77},80,"ESTIMATED","INTERVENTIONAL",[80,81],"PHASE2","PHASE3","Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg\u002Fday for 12 weeks) reduces aging-related arterial stiffening.",[84,85],"Aging","Arterial Stiffness","2026-02-04",{"date":88,"type":89},"2026-02-06","ACTUAL",{"date":91,"type":89},"2024-08-18",{"date":93,"type":77},"2029-02-28",{"name":5,"class":6},1]